When a biologics company is preparing to launch a new product, its manufacturing capacity forecast is subject to a great deal of uncertainty. When firms end up with a supply shortfall, they may learn the hard way that securing additional capacity for biologics is expensive and time consuming. Meanwhile, overestimating demand can waste valuable resources and cut into the bottom line.
Solving this problem is more complicated than just managing volume uncertainty. Biologics developers must consider scale and volume—in that order.